Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
January 09, 2024 07:55 ET
|
Vericel Corporation
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million MACI Full-Year Revenue Expected to be...
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
January 03, 2024 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
November 08, 2023 07:55 ET
|
Vericel Corporation
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5...
Vericel to Present at the Stephens Annual Investment Conference
November 07, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
October 25, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
September 28, 2023 08:30 ET
|
Vericel Corporation
Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared...
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
September 20, 2023 16:30 ET
|
Vericel Corporation
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid...
Vericel to Present at the Morgan Stanley Global Healthcare Conference
September 06, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
August 02, 2023 07:55 ET
|
Vericel Corporation
Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year...
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
July 20, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...